Phaseline

Targets › WNT

WNT: drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on WNT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Katherine GarmanPyrvinium
Wnt pathway inhibitor
WNTPhase 2Gastric Intestinal Metaplasia–
Thomas Jefferson UniversityPyrvinium Pamoate
Wnt/β-catenin pathway inhibitor
WNTPhase 1Resectable Pancreatic Ductal AdenocarcinomaDec 2026
National Cancer Institute (NCI)Cirtuvivint
Wnt signaling pathway inhibitor
WNTPhase 1Acute Myeloid LeukemiaJun 2028

Conditions

Acute Myeloid Leukemia (1) Gastric Intestinal Metaplasia (1) Resectable Pancreatic Ductal Adenocarcinoma (1)

Modalities

small molecule (3)

Companies

National Cancer Institute (NCI) (1) Katherine Garman (1) Thomas Jefferson University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.